TABLE 2.
Susceptibility of the 12 isolates against different antimicrobial agents.
| Antimicrobial agenta | Resistanceb ([n] %) |
MIC (μg/ml) |
|
| 50% | 90% | ||
| IPM | 12 (100) | >8 | >8 |
| MEM | 12 (100) | >8 | >8 |
| PIP | 12 (100) | >64 | >64 |
| AMC | 12 (100) | >16/8 | >16/8 |
| SAM | 12 (100) | >16/8 | >16/8 |
| TZP | 12 (100) | >64/4 | >64/4 |
| CZO | 12 (100) | >16 | >16 |
| CTX | 12 (100) | >32 | >32 |
| CAZ | 12 (100) | >16 | >16 |
| FEP | 12 (100) | >16 | >16 |
| ATM | 12 (100) | >16 | >16 |
| GEN | 12 (100) | >8 | >8 |
| AMK | 12 (100) | >32 | >32 |
| CIP | 12 (100) | >2 | >2 |
| MXF | 12 (100) | >4 | >4 |
| lEV | 12 (100) | >8 | >8 |
| SXT | 5 (41.7) | ≤0.5/9 | >2/38 |
| C | 2 (16.7) | ≤4 | >16 |
| CL | 0 (0) | ≤0.5 | ≤0.5 |
| TET | 5 (41.7) | 8 | >8 |
aIPM, imipenem; MEM, meropenem; PIP, piperacillin; AMC, amoxicillin-clavulanate; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam, CZO, cefazolin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; MXF, moxifloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole; C, chloramphenicol; CL, colistin; TET, tetracycline. b CLSI M100-S28 interpretive criteria were used in all cases, with the exception of MXF and CL, for which EUCAST breakpoints were used.